Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether low-doses alemtuzumab and rituximab
combination are effective in the treatment of chronic graft-versus-host disease (GVHD) after
first-line therapy failure.